MBX (STOCKS)
MBX Biosciences, Inc. Common Stock
$32.990000
+1.990000 (+6.42%)
Prev close: $31.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Peter Kent Hawryluk
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,555.01M
- Employees
- 43
- P/E (TTM)
- -13.56
- P/B (TTM)
- 3.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.49 | $-0.62 | +0.1255 | +20.39% |
|
Sep 2025 (Q3)
|
$-0.63 | $-0.70 | +0.0707 | +10.09% |
|
Jun 2025 (Q2)
|
$-0.58 | $-0.77 | +0.1874 | +24.42% |
|
Mar 2025 (Q1)
|
$-0.71 | $-0.78 | +0.0677 | +8.71% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $98.06M |
| Research and Development | $79.16M |
| Other Operating Expenses | $18.90M |
| Operating Income/Loss | -$98.06M |
| Income/Loss From Continuing Operations After Tax | -$87.00M |
| Income/Loss From Continuing Operations Before Tax | -$87.00M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$86.97M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$86.97M |
| Net Income/Loss Available To Common Stockholders, Basic | -$86.97M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.38 |
| Diluted Earnings Per Share | -$2.38 |
| Basic Average Shares | 36,506,092 |
| Diluted Average Shares | 36,506,092 |
| Assets | $385.14M |
| Current Assets | $381.54M |
| Cash | $373.70M |
| Other Current Assets | $7.84M |
| Noncurrent Assets | $3.61M |
| Fixed Assets | $2.74M |
| Other Non-current Assets | $870.00K |
| Liabilities | $15.92M |
| Current Liabilities | $15.50M |
| Accounts Payable | $2.98M |
| Other Current Liabilities | $12.52M |
| Noncurrent Liabilities | $426.00K |
| Equity | $369.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $369.22M |
| Liabilities And Equity | $385.14M |
| Net Cash Flow From Operating Activities | -$79.95M |
| Net Cash Flow From Operating Activities, Continuing | -$79.95M |
| Net Cash Flow From Investing Activities | -$83.71M |
| Net Cash Flow From Investing Activities, Continuing | -$83.71M |
| Net Cash Flow From Financing Activities | $189.59M |
| Net Cash Flow From Financing Activities, Continuing | $189.59M |
| Net Cash Flow | $25.94M |
| Net Cash Flow, Continuing | $25.94M |
| Comprehensive Income/Loss | -$86.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$86.74M |
| Other Comprehensive Income/Loss | $231.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $231.00K |